• Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.

    Trial setback casts doubt on a biotech's respiratory virus drug

    As vaccines for respiratory syncytial virus progressed, Enanta used its hepatitis C know-how to develop an antiviral pill. Yet data in lower-risk patients raise questions of whether it can work.

    By May 19, 2022
  • Image attribution tooltip
    Permission granted by Odyssey Therapeutics

    Cancer drug startup draws former Vertex CEO to board

    Jeffrey Leiden will team up again with biotech entrepreneur Gary Glick, this time as board chairman of Glick's new company, the recently launched Odyssey Therapeutics.

    By Kristin Jensen • May 19, 2022
  • Explore the Trendline
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    Cell therapy

    Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.

    By BioPharma Dive staff
  • Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals

    Vertex adds to Boston expansion with plans for new site

    The addition, which will be located next to the company's newly dedicated cell and gene facility, could make Vertex the largest biotech by square footage in the city.

    By Kristin Jensen • May 18, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna may seek to claw back payments to ex-CFO

    Jorge Gomez, who lasted one day on the job before being ousted over an investigation at his former company, is owed $700,000 — money Moderna says it can recoup if wrongdoing is proven.

    By Maura Webber Sadovi • May 17, 2022
  • Image attribution tooltip
    Danielle Ternes/BioPharma Dive

    Scientists home in on cause of Duchenne gene therapy side effect

    An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.

    By Updated May 18, 2022
  • Image attribution tooltip
    Jonathan Gardner / BioPharma Dive

    Agios to cut jobs as it moves away from exploratory research

    The biotech expects that, by keeping its focus on more advanced projects and clinical programs, it could save on average $40 million to $50 million annually for the next several years

    By May 16, 2022
  • Image attribution tooltip
    Dimitrios Kambouris / Getty Images for Gabrielle's Angel Foundation via Getty Images

    Seagen CEO Siegall resigns amid domestic violence investigation

    The biotech company is searching for a permanent successor to Clay Siegall, who was arrested last month for alleged domestic violence. CMO Roger Dansey will continue as interim CEO.

    By Updated May 16, 2022
  • Image attribution tooltip
    SciePro via Getty Images

    Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

    The deal hands $275 million upfront to Cullinan, whose medicine is being developed for a genetic driver of lung tumors that's become a top target for drugmakers.

    By Kristin Jensen • May 12, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna's finance head is out as former employer conducts investigation

    Jorge Gomez, who officially took the CFO reins Monday, lasted one day on the job. His departure comes as Gomez's previous company, Dentsply Sirona, looks into financial allegations against current and former executives.

    By May 11, 2022
  • Image attribution tooltip
    Permission granted by Sekar Kathiresan

    In first, Verve gets clearance to test base editing inside the body

    Regulators in New Zealand have allowed human testing to proceed, another milestone for the gene editing technology. Verve plans to soon ask for approval to begin testing in the U.S. and U.K., too. 

    By Kristin Jensen • May 11, 2022
  • Image attribution tooltip
    Permission granted by Moma Therapeutics

    Against a historic market downturn, Moma Therapeutics raises $150M for precision cancer research

    The biotech's Series B round, which kicked off early this year, should fund its work on "molecular machines" until at least 2024, according to CEO Asit Parikh.

    By May 10, 2022
  • Former Novartis exec joins ADC Therapeutics as CEO after brief stint as Rafael head

    Ameet Mallik takes over for founder Chris Martin at helm of the antibody drug developer after a seven-month run leading Rafael Holdings, which reported a clinical trial setback last October.

    By May 9, 2022
  • Image attribution tooltip
    Jacob Bell / BioPharma Dive

    Clay Siegall, founding Seagen CEO, takes leave amid domestic violence accusation

    The company's board is investigating the allegation, which Siegall, who has led Seattle's largest biotech for 24 years, denied. Chief Medical Officer and former Merck executive Roger Dansey was named interim CEO.

    By May 9, 2022
  • Image attribution tooltip

    James Thew/

    Sponsored by TrialCard

    PatientLink by TrialCard: The digital patient support platform

    New offering aligns with industry shift towards healthcare consumerism and empowers life science leaders to deliver highly personalized patient support experiences.

    May 9, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Argenx drug succeeds in trial, beats sales forecasts

    The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations.

    By Kristin Jensen • May 5, 2022
  • Image attribution tooltip
    Getty Images: Edited by BioPharma Dive

    Intercept sells international rights to liver drug in $400M deal

    Advanz Pharma will obtain rights to Ocaliva outside the U.S., handing its maker an upfront payment nearly equivalent to its market value.

    By May 5, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

    Though executives claimed that inking deals and derisking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term. 

    By May 4, 2022
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna vaccine sales surpass expectations as company looks to fall boosters

    The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

    By May 4, 2022
  • Image attribution tooltip

    Regeneron tries to shake off fall in COVID drug sales with first quarter earnings

    Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread.

    By Kristin Jensen • May 4, 2022
  • Image attribution tooltip
    utah778 via Getty Images

    Spero to lay off 75% of workforce, change strategy after FDA challenges study results

    Agency statisticians took a different view of the Phase 3 results the biotech was relying on to support approval of a new antibiotic, an announcement that triggered the sector's latest restructuring.

    By May 4, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen CEO to step down as company pulls back from Alzheimer's drug

    Michel Vounatsos, Biogen's CEO since 2017, will be replaced as the company "substantially" eliminates the commercial workforce around Aduhelm, which has generated paltry sales in the face of resistance from insurers and doctors.

    By Updated May 3, 2022
  • Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.

    A cancer biotech attracts another deep-pocketed partner in Gilead

    Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."

    By May 2, 2022
  • Image attribution tooltip

    AbbVie's first shot at Vertex misses, but it's not abandoning cystic fibrosis

    Executives on Friday said that the company's three-drug therapy, a possible threat to Vertex's top-selling medicine Trikafta, didn't meet expectations in a key study. A new combination could start testing next year, however.

    By April 29, 2022
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    After setbacks, a gene therapy company mulls a sale

    Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs.

    By April 28, 2022
  • Image attribution tooltip
    400tmax via Getty Images

    Two biotechs set out to end sector's IPO drought

    HilleVax and Belite Bio could soon become the first biotechs to go public in almost two months, representing a key test of investors’ willingness to support emerging life sciences companies.

    By April 27, 2022